

1 Physicians' Attitudes towards Secondary Use of Clinical Data for
2 Biomedical Research Purposes in Germany. Results of a
3 Quantitative Survey.

4 Anja Köngeter¹, Christoph Schickhardt², Martin Jungkunz², Katja Mehlis^{¶1}/ Eva C.
5 Winkler*^{¶1}

6
7 ¹Section for Translational Medical Ethics, Department of Medical Oncology, National
8 Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany

9 ²Section for Translational Medical Ethics, Department of Medical Oncology, National
10 Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany

11

12 [¶] These authors contributed equally to this work.

13 * Corresponding Author:

14 Prof. Dr. med. Dr. phil. Eva C. Winkler

15 National Center for Tumor Diseases (NCT)

16 Department of Medical Oncology, Section for Translational Medical Ethics,

17 Heidelberg University Hospital

18 Im Neuenheimer Feld 460

19 69120 Heidelberg, Germany

20 Phone: 0049 6221/56-36049

21 E-Mail: eva.winkler@nct-heidelberg.de

22

23 **Abstract**

24 **Background:** For biomedical data-driven research purposes, secondary use of clinical
25 data carries great but largely untapped potential. Physicians' attitudes and their needs
26 towards secondary data use are essential to inform its practical and ethically sound
27 implementation but are currently understudied.

28 **Objective:** Therefore, the objectives of the study are to assess physicians' (i) general
29 attitudes and concerns, (ii) willingness to adapt workflows and to make data available for
30 secondary use, (iii) group-specific conditions and concerns of physician-scientists and
31 purely clinical physicians.

32 **Methods:** We developed an online survey based on a literature review and an expert
33 interview study. Physicians in private practice and at two large German university
34 hospitals were surveyed from May 2021 until January 2022.

35 **Results:** In total, 446 physicians participated in the survey. 96% [380/397] of all
36 physicians reported a positive attitude towards secondary use; 87% [31/397] are in-
37 principle willing to support secondary use of clinical data along with a small proportion
38 of physicians with fundamental reservations 8%. Secondly, the most important conditions
39 for adapting workflows was funding of additional time and effort for research-adequate
40 documentation (71% [286/390]) and the most important condition for providing
41 patients' clinical data was reliable protection of patients' privacy (67% [254/382]).
42 Thirdly, physician-scientists were more likely to request additional funding for research-
43 adequate documentation as a precondition for support (83% vs 69%, $P=.002$) and the
44 privilege to conduct research with patient data prior to other researchers (43% vs 11%,
45 $P<.001$); while purely clinical physicians more frequently require reliable protection of
46 patient privacy (76% vs 62%, $P=.007$) and monetary compensation (45% vs 25%,
47 $P<.001$).

48 **Conclusion:** Since this study presents high in-principle willingness of physicians to
49 support secondary use along with little general concerns, it seems essential to address
50 physicians' group-specific conditions toward secondary use in order to gain their support.

51

52 **Keywords:** secondary use; data sharing; data access; physician attitudes; physician-
53 scientists; health data; clinical data;

54 **Introduction**

55 Secondary use of clinical data for biomedical research purposes holds promising potential
56 for various types of non-interventional, data-driven research. We define secondary use as
57 the collection and reuse of clinical data in data-gathering, non-interventional biomedical
58 research and quality improvement activities (1). Research with clinical data collected in
59 routine care bears the advantage of not involving additional physical interventions or the
60 collection of additional data. In Germany, the medical informatics initiative, funded by the
61 German Federal Ministry of Education and Research, aims at fostering secondary use of
62 clinical data from health care facilities (2). Although secondary use aims to improve
63 biomedical knowledge and thus medical care, it is highly unlikely to directly benefit the
64 patients who released their data.

65 Physicians' attitudes towards secondary use have hardly been investigated. Some studies
66 have focused on related topics. For example, a systematic literature review about
67 researchers' and health care professionals' perspectives on data sharing of clinical trial
68 data and health administrative data pinpoints major concerns related to privacy, access
69 to data, and potential for misinterpretation of data (3); data to be shared are defined
70 differently in these studies, and sometimes are not clearly characterized. Several
71 *qualitative* studies highlight concerns related to secondary use of different kinds of health
72 data in general practitioners (GPs) (4-7) and oncologists (8). So far, it is unclear how
73 pronounced and widespread these concerns are.

74 The scarce socio-empirical evidence is unsatisfying given the relevance of physicians'
75 support for the implementation of new workflows as suggested by an exploratory
76 interview study we conducted in preparation for the present survey: experts considered
77 willingness of physicians to provide support for the implementation of secondary use in
78 German hospitals and private practices both critical and possibly insufficient (9); one GP

79 stated that peers would be reluctant to change their work routine. Regarding monetary
80 incentives to change work routine, two qualitative studies of Australian GPs come to
81 contradictory conclusions (4, 5). To our knowledge, there are no quantitative studies that
82 examine whether and under what conditions physicians are willing to adjust their work
83 routine for secondary use.

84 So far, group distinctions between physician-scientists and purely clinical physicians have
85 not been examined. However, two studies indicate disparities between these groups:
86 While Canadian health researchers widely accepted secondary use for research (10)
87 whereas Canadian GPs showed a far lower approval rate (11).

88 The aim of this study is therefore to assess physicians' attitudes and group-specific needs
89 regarding secondary use which can inform its practical implementation. To address the
90 delineated research gap, the objectives of the present study are to assess physicians' (i)
91 general attitudes and concerns, (ii) in-principle willingness to adapt workflows to share
92 data for secondary use, (iii) group-specific conditions to support secondary use in
93 physician-scientists and purely clinical physicians. To our knowledge, we present the first
94 quantitative analysis of physicians' conditions to support secondary use of clinical data
95 for research purposes and the first study differentiating between physician-scientists' and
96 purely clinical physicians' needs.

97

98 **Methods**

99 **Survey Development**

100 The questionnaire is based on a literature review and the results of an expert interview
101 study (9). The expert interviews indicated distinct perceptions and expectations of
102 physician-scientists and purely clinical physicians. Therefore, we derived group-specific
103 hypotheses that we operationalized in the form of questionnaire items. The questionnaire

104 was developed and discussed with members of an interdisciplinary research team
105 consisting of social scientists, ethicists, legal scholars, and physicians. To ensure
106 comprehensibility and technical function of the 22 item questionnaire, we pretested the
107 survey by cognitive interviews (n=6) with physicians with and without experience in
108 generating and using clinical data for research purposes. Based on the results, we adjusted
109 the wording of the specific conditions for physicians' support to improve
110 comprehensibility.

111 The survey included information about risks and benefits to patients associated with
112 secondary use as well as the potential increase in documentary workload for clinicians to
113 allow participants to develop an informed opinion. The self-administered, anonymous,
114 online survey covered attitudinal questions designed as 5-point Likert scale.
115 Measurement of pronounced research interest was operationalized by asking
116 participants define themselves as physician-scientists; participants who do not define
117 themselves as physician-scientist were referred to as purely clinical physicians. The study
118 obtained ethics approval from the University of Heidelberg's research ethics committee
119 (reference number S-361/2018). This survey was approved by the data protection officer
120 of Heidelberg University Hospital. These approvals were valid for all data collections.

121 **Sampling and recruitment**

122 The survey was administered via three data collections: For the first data collection the
123 Cancer Registry of the German federal state of Baden Wuerttemberg sent e-mail
124 invitations to physicians in Baden Wuerttemberg who had reported more than two
125 patients in the registry until April 2021 (census, N=3.313). The 2nd and the 3rd data
126 collections complemented the first and was targeted to physicians at university hospitals
127 and thereby a research-oriented environment. For the 2nd data collection at the Heidelberg
128 University Hospital (census, N=1,686) an e-mail distribution list of all physicians with

129 patient contact was created and was authorized by the university hospital board and the
130 employee council. And for the *3rd data collection* all physicians of the Charité - University
131 Hospital Berlin were invited via email by the Charité-BIH Clinical Study Center (census,
132 N=3,870). All e-mail invitations contained a weblink to the anonymous survey.
133 Individuals who completed the survey were not compensated. Data collections occurred
134 from May 2021 until January 2022 with a duration of 3-4 weeks each. For the 2nd and 3rd
135 data collection, an e-mail reminder was sent out 8 days after the first invitation.

136 **Analysis**

137 Descriptive statistics were used to express categorical variables as counts and
138 percentages. Differences in proportions were assessed for statistical significance ($P <$
139 0.05) by way of χ^2 tests. Significances of group differences in mean values were calculated
140 using the Mann-Whitney U test (two-tailed). All analyses were performed using SPSS IBM
141 version 28.

142

143 **Results**

144 **Participant characteristics**

145 Of the 8,615 physicians contacted, 446 responded to the survey (response rate: 5%); after
146 excluding participants who answered less than 50% of the items or dropped out before
147 item no. 11, the dataset used for analysis encompassed 397 cases. Of these included
148 physicians, 79% [313/397] worked at a university hospital and 15% [60/397] in a private
149 practice (Table 1). Gender distribution was balanced. 62% [245/397] reported more than
150 10 years of work experience'.

151 Overall, 63% [251/397] indicated perceiving themselves as physician-scientist; at
152 university hospitals 84% [243/294] of all physicians considered themselves physician-

153 scientists. 31% [125/397] were defined as purely clinical physicians by indicating that
 154 they do not perceive themselves as physician-scientists; 98% [57/58] of all physicians
 155 working in private practice were purely clinical physicians. Of all participants, 81%
 156 [321/397] reported having contributed to studies using clinical data in the last 5 years.

157 **Table 1. Demographics of participants (n=397)**
 158

Characteristics	Values, n (%)
Affiliation	
University Hospital / Academic Teaching Hospital	313 (78.64)
Private practice	60 (15.08)
Public community hospitals and for-profit hospitals	20 (5.03)
n/a	4 (1.26)
Years of Service	
≤ 10	150 (37.69)
> 10	245 (61.56)
n/a	2 (0.50)
Medical Speciality (top five)	
Internal Medicine	88 (22.11)
Surgery	39 (9.80)
Gynecology	39 (9.80)
Anesthesiology	29 (7.29)
Pediatrics and Youth Medicine.	25 (5.53)
Sex	
Female	180 (45.23)
Male	207 (52.01)
n/a	10 (2.52)
Identifies as physician-scientist	
Yes	251 (63.07)
No	125 (31.41)
n/a	21 (5.29)
Involved in conducting studies using clinical data from patient care within the last 5 years	
Yes	321 (80.65)
No	72 (18.09)
n/a	4 (1.01)

159

160 **General attitudes towards supporting secondary use**

161 With 96% [380/397] almost all respondents deemed secondary data use for research
162 purposes important and 68% [269/397] hold the view that, as a physician, they have a
163 moral obligation to provide clinical data from patient care for research purposes (Fig 1).
164 Only 8% [31/397] of the participants had fundamental reservations. Yet, 13% [50/397]
165 of respondents were concerned that patients would report fewer details about their
166 illness and 11% [41/397] of physicians would document differently to protect their
167 patients' sensitive information (e.g. stigmatizing data) against misuse; purely clinical
168 physicians expressed significantly stronger fundamental reservation (\bar{x} =2.04 vs \bar{x} =1.50,
169 $P<.001$), were more concerned that their patients will report fewer details (\bar{x} =2.32 vs
170 \bar{x} =1.93, $P=.001$), and were more inclined to change their way of documentation (\bar{x} =2.12
171 vs \bar{x} =1.73, $P=.001$) compared to physician-scientists (*Table 2*).

172 87% [348/390] of all surveyed physicians were willing to support secondary research use
173 in principle. When being asked about potentially necessary adjustments of the workflow,
174 71% [286/390] were willing to implement changes for documentation, and 67%
175 [269/390] were willing to inform and consent patients for secondary use. In contrast to
176 purely clinical physicians, physician-scientists were more convinced about the
177 importance of secondary use (\bar{x} =4.90 vs \bar{x} =4.53, $P<.001$), more willing to adjust
178 documentation (\bar{x} = 4.14 vs \bar{x} =3.56, $P<.001$), and more willing to obtain informed consent
179 (\bar{x} =4.09 vs \bar{x} =3.48, $P<.001$).

180

181 **Figure 1: General attitudes and concerns of physicians towards secondary use of clinical data for research purposes and**
 182 **their willingness to support secondary use**

183

184 **Table 2: Significance of differences in general attitudes toward secondary use and willingness to support secondary use by**
 185 **self-perception as physician-scientist and purely clinical physician**

Agreement to Statement	Physician scientist, mean (SD)	Purely clinical physician, mean (SD)	P value^a
I think it is fundamentally important that patients' clinical data be used for research purposes. (n = 397)	4.90 (0.41)	4.53 (0.85)	<.001
I am generally willing to support research using my own patients' clinical data. (n = 397)	4.66 (0.81)	4.12 (1.14)	<.001
As a physician, I have a moral obligation to provide clinical data from patient care for research purposes (if patients consent to this use). (n = 397)	4.12 (1.12)	3.56 (1.27)	<.001
In principle, I am prepared to implement any necessary adjustments to workflows in documentation for research purposes as part of my job. (n = 390)	4.14 (1.00)	3.56 (1.16)	<.001
In principle, I am prepared to implement any necessary adjustments to workflows with regard to information and consent processes as part of my job. (n = 390)	4.09 (1.02)	3.48 (1.19)	<.001
I have fundamental reservations about supporting research with clinical data from my own patients. (n = 397)	1.50 (0.91)	2.04 (1.22)	<.001
I am concerned that my patients will report fewer details about their conditions if they know that their clinical data will be used for research purposes. (n = 397)	1.93 (1.05)	2.32 (1.16)	.001
If my patients' clinical data is collected for research, I will document differently to protect my patients' data against misuse (e.g., I will not document stigmatizing diagnoses). (n = 397)	1.73 (1.03)	2.12 (1.21)	.001

^a Significances of group differences in mean values were calculated using the Mann-Whitney U test; Values in italics are significant at .05 level of significance (two-tailed); 5 Point Likert Scale: Disagree 1; Agree 5.

186 **Conditions for adapting workflows**

187 Participants were then asked to indicate what seems most important to them for adapting
 188 their workflows in order to support secondary data use. They did so by selecting the three
 189 most important conditions out of a list. The most frequently selected conditions were
 190 funding of additional person-hours for research-appropriate documentation (77%
 191 [302/390]), funding of newly developed and user-friendly software to support research-
 192 appropriate documentation (62% [243/390]), and funding of additional person-hours for
 193 obtaining informed consent (60% [236/390]) (*Table 3*). Physicians-scientists and purely
 194 clinical physicians differed in only one aspect; funding of additional person-hours for

195 research-adequate documentation was more important to physician-scientists (83% vs
 196 69%, $P=.002$).

197

198 **Table 3: Conditions for adapting workflows for secondary use (documentation and obtain consent); significance of group**
 199 **differences (n=390)**

200

	All participants, n (%)	Physician-scientists, n (%) ^b	Purely clinical physicians, n (%) ^b	<i>P value</i> ^c
Conditions to implement adaptations of the workflows^a				
Funding for additional person-hours for research-appropriate documentation	302 (77.44)	205 (82.66)	83 (68.60)	<i>.002</i>
Funding of newly developed, user-friendly software to support research-appropriate documentation	243 (62.31)	162 (65.32)	67 (55.37)	.064
Funding for additional person-hours for patient information related to consent	236 (60.51)	153 (61.69)	71 (58.67)	.578
Improving the quality of care across the healthcare system	123 (31.54)	77 (31.04)	38 (31.40)	.945
Improving the quality of care in one's own practice/department through feedback systems fed by the analysis of clinical data from all integrated practices/departments - including one's own practice/department	89 (22.82)	50 (20.16)	35 (28.92)	.061
Free access to publications based on routine care clinical data	69 (17.69)	40 (16.12)	26 (21.48)	.207
Certificate in recognition of generating high-quality clinical data for research purposes	23 (5.90)	17 (6.85)	6 (4.95)	.479

^a Multiple Answer item; maximum 3 answers.

^b Of all participants who answered this item (n=390), n= 369 indicated whether or not they consider themselves physician-scientists (n=248) or physicians (n=121).

^c Chi-Squared Test (Pearson); values in italics are significant at .05 level of significance.

201

202 When asked about participants' willingness to spend additional time for research-
 203 adequate documentation per patient visit, 53% [165/314] of the participants was willing
 204 to document up to additional 2-6 minutes, 25% [79/314] of the participants to document
 205 up to 2 minutes, and 22% [70/314] was willing to document ≥ 6 minutes. A significantly
 206 larger proportion of physician-scientists were willing to document ≥ 6 minutes
 207 compared to purely clinical physicians (28% vs 11%, $P=.005$).

208 63% [249/386] of respondents favoured trained, non-medical staff to inform and consent
 209 patients about secondary use; 31% [123/386] felt themselves, as physicians, responsible
 210 for this task.

211

212 **Conditions for providing patients' clinical data**

213 All participants were asked about conditions they deem most important in order to make
214 their patients' clinical data available for secondary use. The most frequently reported
215 conditions were: reliable protection of patients' privacy (66% [254/382]), extra
216 protection for sensitive data (e.g., genetic data, psychiatric data) (47% [179/382]), and
217 notification about additional/incidental findings relevant to their patients' health (37%
218 [140/382]) (Table 3).

219 Patient privacy was significantly more often important to purely clinical physicians than
220 to physician-scientists (76% vs 62%, $P=.007$) as was the monetary compensation for
221 making research-adequate clinical data available (45% vs 25%, $P<.001$). For Physician-
222 scientists the right to first conduct their own research with their patients' clinical data
223 was more relevant (43% vs 11%, $P<.001$) as was co-authorship in scientific articles based
224 on clinical data of their patients (31% vs 8%, $P<.001$).

225

226

227 **Table 4: Conditions for providing patients' clinical data available for medical studies and significance of differences in**
 228 **proportions by self-perception as physician-scientist or physician (n=382)**
 229

	All participants, n (%)	Physician-scientists, n (%) ^b	Purely clinical physicians, n (%) ^b	P value ^c
Conditions to make your patients' clinical data available^a				
Reliable protection of the privacy of my patients	254 (66.49)	149 (61.57)	91 (75.83)	.007
Special protection measures for sensitive data (e.g. genetic data, psychiatric data)	179 (46.85)	108 (44.62)	61 (50.83)	.265
Notification of additional diagnostic findings in my patients that will be identified in the future as a result of planned research use of clinical data (for example, through novel methods of analysis of image data)	140 (36.64)	82 (33.88)	50 (41.66)	.148
Right to initially conduct my own research with my patients' clinical data	125 (32.72)	104 (42.97)	13 (10.83)	<.001
Monetary compensation for providing appropriately generated datasets suitable for research purposes	122 (31.93)	60 (24.79)	54 (45.00)	<.001
Co-authorship of scientific journal articles that use my patients' data	91 (23.82)	75 (30.99)	10 (8.33)	<.001
Only with my permission or the permission of my supervisor will researchers receive the clinical data of my patients (without identifying information)	60 (15.70)	45 (18.59)	15 (12.50)	.142
Mention my department/practice in scientific journal articles that use my patients' data	37 (9.69)	24 (9.92)	13 (10.83)	.787
Mention my name in the acknowledgements of scientific journal articles that use my patients' data	13 (3.40)	9 (3.80)	3 (2.50)	.542

^a Multiple Answer item; maximum 3 answers.

^b Of all participants who answered this item (n=382), n= 369 indicated whether or not they consider themselves physician-scientists (n=242) or physicians (n=120).

^c Chi-Squared Test (Pearson); values in italics are significant at .05 level of significance.

230
 231 Being asked about the acceptance of potential data-users, 40% [159/381] of respondents
 232 agreed that all researchers, regardless of their affiliation, should be allowed to use their
 233 patients' clinical data. 46% [174/381] were opposed to making clinical data available for
 234 researchers working for companies conducting medical research. 18% [67/381] did not
 235 want to provide data for collaborative projects between public research institutions and
 236 private companies.
 237 Participants were asked about data ownership. They were divided on whether data can
 238 be owned (51%) or not (49%). Among those who held that data can be owned, 54%

239 considered patients as data owners, and 40% believed that the practices and hospitals
240 where data are collected or the physicians own the data, and only 6% thought the data
241 belong to everyone who can use the data to add value to medical care. Purely clinical
242 physicians were significantly more likely to think that data belong to patients (66% vs
243 48%, $P=.024$). Interestingly, the view that data can be owned was positively associated
244 ($\eta^2=.191$ $P<.001$) with the willingness to provide patients' clinical data.

245

246 *Concerns about provision of patient data*

247 Participants were asked about their specific concerns with respect to the provision of
248 their patients' clinical data for secondary use. These concerns differed significantly
249 between the two groups (*Table 4*). Compared to physician-scientists, purely clinical
250 physicians were significantly more likely to have concerns about misuse of their patients'
251 clinical data through unauthorized access to datasets by third parties (75% vs 53%,
252 $P<.001$), failure to protect their patients' privacy (62% vs 36%, $P<.001$), and
253 discrimination based on clinical data against their patients (27% vs 15%, $P=.009$). Purely
254 clinical physicians were also more likely to have concerns about increased liability risk
255 (e.g., research uncovers a misdiagnosis in their own practice/department) (36% vs 26%,
256 $P=.044$), and a loss of patients' trust in the physician-patient relationship (21% vs 12%,
257 $P=.019$). The second most common concern of physician-scientists (after concerns about
258 privacy of their patients) was insufficient data quality that can result in inaccurate
259 findings (62% vs 42%, $P<.001$), and that other researchers conduct research using their
260 patients' clinical data before they do (43% vs 13%, $P<.001$).

261

262

263 **Table 5: Concerns about providing patients' clinical data for secondary use and significance of group differences (n=382)**

264

	all participants, n (%)	physician-scientists, n (%) ^b	Purely clinical physicians, n (%) ^b	<i>P</i> value ^c
Concerns about making patients' clinical data available^a				
Misuse of data through unauthorized access to data records	229 (59.94)	127 (52.47)	90 (75.00)	<i><.001</i>
Insufficient data quality, which can cause studies to produce erroneous results	215 (56.28)	151 (62.39)	50 (41.66)	<i><.001</i>
Failure to adequately protect the privacy of my patients	174 (45.54)	87 (35.95)	74 (61.66)	<i><.001</i>
Other researchers conduct research using the clinical data from my practice/department before I do	124 (32.46)	104 (42.97)	15 (12.50)	<i><.001</i>
Novel liability issues/increased liability risk (e.g., research uncovers misdiagnosis in own practice/department)	115 (30.10)	62 (25.61)	43 (35.83)	<i>.044</i>
New technological developments with new possibilities for re-identification carry the potential for harm to my patients	89 (23.29)	51 (21.07)	32 (26.66)	<i>.233</i>
Discrimination against my patients on the basis of their clinical data, e.g. in the case of re-identification of individual patients or on the basis of belonging to a group with a certain disease or disposition	74 (19.37)	37 (15.28)	32 (26.66)	<i>.009</i>
Performance comparisons with other practices/departments at hospitals conducted using clinical data from external agencies	71 (18.58)	47 (19.42)	21 (17.50)	<i>.659</i>
Loss of trust in the doctor-patient relationship on the part of the patients	61 (15.96)	28 (11.57)	25 (20.83)	<i>.019</i>
Future studies pursue research purposes that harm my patients	31 (8.11)	16 (6.61)	11 (9.16)	<i>.384</i>

^a Multiple Answer item.

^b Of all participants who answered this item (n=382), n= 369 indicated whether or not they consider themselves physician-scientists (n=242) or physicians (n=120).

^c Chi-Squared Test (Pearson); values in italics are significant at .05 level of significance.

265

266 **Discussion**

267 **Main Findings**

268 Information on whether and under what preconditions physicians are willing to make
 269 their patients' clinical data available for research is vital for practical and ethically sound
 270 implementation of secondary use. Here we report results of a survey among 397
 271 physicians working in two university medical centres and in private practice on their
 272 general attitudes, concerns, in-principle willingness and conditions for enabling support

273 of secondary use of clinical data for research purposes. To our knowledge, we present the
274 first quantitative analysis of physicians' conditions to support secondary use of clinical
275 data for research purposes.

276 Firstly, we found a highly positive general attitude of physicians towards secondary use
277 along with little fundamental reservations. Secondly, physicians showed widespread in-
278 principle willingness to support secondary use; most important conditions for practical
279 implementation were reliable protection of patients' privacy as well as funding of
280 additional person-hours for documentation and consenting patients. Third, group specific
281 differences were prevalent: Physician-scientists were more likely to be concerned about
282 data quality, required additional funding for research-adequate documentation and the
283 right to first conduct research with their patients' clinical data; in contrast, purely clinical
284 physicians were more prone to be concerned about patient privacy and the physician-
285 patient relationships, and to require, hence, reliable patient privacy as well as monetary
286 compensation.

287

288 **High in-principle willingness for supporting secondary use**

289 Despite methodological and thematic differences that limit comparability, we aim to
290 embed our findings carefully within related studies. Among all 397 surveyed physicians,
291 a very high proportion of physicians were of the view that secondary use is important
292 (96%) and were in-principle willing to support secondary use (87%). This corresponds
293 with a previous survey in a small sample in Canadian health researchers presenting the
294 very strong general acceptance (96%) of using "citizens' health data for research" (10).
295 Our study further found a majority of physicians viewing the support of secondary use as
296 a moral duty of peer physicians (68%). This view resonates with the results of a study we
297 have previously conducted in which cancer patients attributed an obligation to their

298 physicians to support secondary use (91%) (12). An ethical discussion of such a duty to
299 support secondary use seems essential in order to resolve the tension of conflicting duties.
300 Only few physicians expressed fundamental reservations about secondary use (8%). This
301 finding helps to classify the importance of qualitative studies that emphasized widespread
302 and severe concerns to the German context (4, 5, 11).
303 This study showed that making clinical data available for researchers who work for
304 companies and conduct medical research was acceptable for the majority of physicians
305 (40%). This aspect was previously considered problematic in qualitative studies among
306 physicians (5, 8, 13). Acceptance rate of data use by company researchers in our study
307 was considerably higher than in a small sample of GPs conducted in Canada being asked
308 for use of electronic health record data for research by pharmaceutical industry (9%;
309 n=46) (11). This discrepancy should be examined in a more nuanced way with a focus on
310 types of data use and consideration of wordings such as 'pharmaceutical industry' which
311 could carry negative connotations. Physicians were more willing to support secondary
312 use in case of public-private-partnerships which is consistent with findings of a
313 qualitative study with GPs conducted in the UK that indicate a higher level of trust in
314 public-private partnerships than in companies (6).

315

316 **Most important conditions for practical implementation**

317 *Adjustment of workflows*

318 About three-quarters of physicians were in principle willing to adjust their workflows to
319 support secondary use (76%). Physicians were most interested in keeping expenditures
320 in terms of time, personnel and money to a minimum. This is consistent with a Canadian
321 qualitative study in GPs identifying uncompensated staff time as a major hurdle (5).
322 Studies report that physicians being already increasingly dissatisfied with more and more

323 time occupied for documenting in electronic health records for medical care – meaning
324 even without documentation for research purposes - at the expense of time spent in
325 contact with patients (14, 15). One quantitative study even suggests electronic health
326 record use being related to burnout (16). Hence, physicians will likely be sensitive
327 towards additional time and work that could further reduce contact time with their
328 patients. While physicians in this study indicated that additional documentation time per
329 patient visit of 5 minutes on average would be acceptable for them, they also specifically
330 requested extra funding for personnel for research-adequate documentation of data
331 (77%). Software solutions might be apt to reduce the burden of documentation, if they
332 decrease time for documentation significantly (17), and cover a range of functional tasks
333 (18). Healthcare personnel and hospital management should be directly involved in the
334 development of new workflows and software at an early stage (4) to prevent disruption
335 of complex workflows.

336 The majority of physicians agreed that non-medical staff should consent patients for
337 secondary use (62%). We suppose that physicians clearly distinguish consent to
338 interventional clinical trials from consent to *non-interventional* secondary research use.
339 Hence, obtaining informed consent for secondary use by trained, non-medical staff by
340 default is worth considering.

341

342 *Provision of patient data*

343 In contrast to physician-scientists, purely clinical physicians were less inclined to be in
344 principle willing to make their patients' clinical data available for research purposes
345 ($\bar{x}=4,66$ vs $\bar{x}=4,12$, $P<.001$). Although comparability is limited due to differences in the
346 study population this finding is in line with a survey among GPs from Canada with
347 moderate acceptance rate of sharing patient data with university researchers (60%) (10).

348 Also, purely clinically oriented physicians were more likely to see patients as the owner
349 of the data while overall the positions on the question whether data can be owned at all
350 was quite divided. This reflects the controversial ethical debate about the concept of
351 ownership with regard to health data where convincing arguments would rather support
352 ownership in a sense of control and engagement than in the sense of property (19).

353 The most important condition on the part of physicians to make clinical data available for
354 secondary use was the reliable protection of patient privacy (67%). This finding is
355 consistent with existing literature indicating that physicians feel responsible for patient
356 privacy and view themselves as data custodians (5, 20). Therefore, reliable data security
357 and data protection should be implemented, the question of data ownership should be
358 clarified, and physicians should be informed transparently about data protection
359 measures of data initiatives (and also about data leaks if they occurred) so that trust in
360 secondary use can be built.

361 Feedback systems that help physicians to improve internal quality and recognition of
362 their efforts to contribute to a learning healthcare system might strengthen the link
363 between care and research.

364

365 **Addressing physician-scientists' research interests**

366 We found that physician-scientists and purely clinical physicians differed systematically
367 in terms of conditions they place on and concerns they have about secondary use.
368 Physician-scientists' research experiences and interests might be the reason for their
369 significantly stronger concerns about insufficient data quality for research purposes. This
370 finding is in line with a mixed-method study showing concerns about data quality among
371 health researchers (21). To ensure physician-scientists' trust in research-adequate data
372 quality, implementing appropriate measures and resources for high quality

373 documentation should receive high priority. Physician-scientists were also more likely
374 than purely clinical physicians to demand additional funding for research-adequate
375 documentation. According to literature, support for physician-scientists is needed to
376 perform research activities alongside patient care (22).

377 Simultaneously, physicians should be made aware that their documentation practices
378 have direct consequences for the scientific usability of clinical data and for the quality of
379 research results.

380 Compared to purely clinical physicians, physician-scientists emphasised significantly
381 more often the privilege to conduct research with patient data prior to other researchers.
382 A systematic literature review demonstrated that health researchers want to exert some
383 control over data they had collected (3). Hence, potential rights of – time-limited -
384 exclusive use might facilitate the implementation of secondary use, but need to be
385 weighed against the argument of maximizing utility of data generated in a publicly funded
386 healthcare system. Additional measures might be co-authorship or other ways of
387 recognition.

388

389 **Addressing purely clinical physicians' interests**

390 Purely clinical physicians were significantly more often concerned than physician-
391 scientists about their patients losing trust in the physician-patient relationship if data
392 are made available for secondary use. Such concerns have not been reported so far. Purely
393 clinical physicians were also more likely to be concerned about protection of their
394 patients' privacy and placed reliable privacy protection as the most important condition
395 to support secondary use. They even reported to protect their patients' data by
396 documenting differently. According to the literature, trust in data users seems to be a vital
397 facilitator for secondary use (5, 21, 23) as well as a trustworthy governance structure and

398 oversight bodies, e.g. use and access committees (24) (13). To build trust in data
399 infrastructure and governance of secondary use, ensuring and communicating patient
400 privacy protection is a fundamental prerequisite, particularly for purely clinical
401 physicians.

402 An important incentive for purely clinical physicians was monetary compensation of
403 expenses for secondary use. Since almost all purely clinical physicians work in private
404 practices, this finding might reflect their economic situation as mostly self-employed
405 entrepreneurs. Since purely clinical physicians typically do not plan to use and directly
406 benefit from the preparation and provision of data, fair compensation schemes seem
407 imperative for this group (5).

408

409 **Limitations**

410 The low response rate (5%) reflects difficulties to motivate physicians to participate in
411 studies have been recognized (25) with reasons for non-participation such as survey
412 fatigue and minimal time resources. Also, the subject of the present study does not
413 directly address topics relevant to patient care which may have further reduced interest
414 in participation. Given the low response rate, self-selection bias cannot be ruled out. The
415 high proportion of physicians working at university hospitals might lead to a study
416 population with increased thematic (research) interest, possibly overstating positive
417 attitude towards secondary use. We used a self-developed questionnaire without
418 validated measurement instruments, yet tested by cognitive interviews. The sample is not
419 representative of the German medical profession, yet our results may provide indications
420 of relevant needs and concerns of physicians in Germany.

421 We assumed that organizational background exerts relevant influence on physicians'
422 attitudes toward secondary use as physicians working in private practice potentially feel

423 more in charge for data protection standards of their practice than physicians working in
424 a hospital. The distinction between physicians working in hospitals and in private practice
425 needs further assessment in a larger dataset to inform implementation of secondary use
426 in different organisational settings.

427

428 **Conclusion**

429 This first quantitative study on the perspective on secondary health data use of physicians
430 in an research prone environment compared to those in private practice should inform
431 further studies and the setup of infrastructures for secondary use of clinical data in
432 Germany and possibly beyond. We found high in-principle willingness of physicians to
433 support secondary use and low general concerns. High in-principle willingness and little
434 concerns indicate the importance of considering physicians' demands and conditions in
435 order to foster secondary use: most important conditions were protection of patient
436 privacy and manageable expenses in terms of time, personnel and money. If extra
437 expenses occur, the provision of funding to compensate for them is expected such as
438 medical documentation specialists, non-medical staff obtaining consent, and user-centred
439 documentation software - in order to not further reduce contact time with patients.
440 Adaptation of workflows for research-adequate documentation and consenting patients
441 should be pilot-tested in participatory (research) formats in order to prevent disruption
442 of complex clinical processes.

443 Our results demonstrated group-specific differences. *Physician-scientists'* answers
444 mirrored the rationales of the scientific system with concerns about research-adequate
445 data quality, requesting incentives such as the privilege of first conducting research and
446 funding for research-adequate documentation. Building trust in data repositories and its
447 users seems essential for physician-scientists' support and readiness to conduct research

448 with clinical data themselves. *Purely clinical physicians* were concerned about patients'
449 privacy and about a possibly worsening physician-patient relationship. Their most
450 important condition for support of secondary use was the protection of patient privacy
451 but also monetary compensation which can be attributed to the often self-employed work
452 in private practices performed by this group. Besides establishing monetary
453 compensation schemes, for purely clinical physicians, relevant conditions to support
454 secondary use include ensuring and communicating patient privacy protection
455 accompanied by a trustworthy data governance structure that enables transparent data
456 use.

457

458 **Acknowledgements**

459 Ethics approval and consent to participate

460 Informed consent was obtained from individuals who participated in the study pretests
461 and the written survey. The datasets generated and analyzed in the current study are
462 available online (<https://doi.org/10.11588/data/5JCEVW>).

463 This manuscript was developed within the framework of the project "Learning from
464 Clinical Data (LinCDat)" funded by the Deutsche Forschungsgemeinschaft (DFG, German
465 Research Foundation) – 406103282. The project funding was awarded to ECW. The
466 funders had neither involvement in study design; in the collection, analysis and
467 interpretation of data; in the writing of the report, nor in the decision to submit the article
468 for publication. There was no additional external funding received for this study.

469 All authors contributed to the study conception and design. Material preparation, data
470 collection and analysis were performed by AK and KM. ECW and KM supervised the work
471 and supported data interpretation. The first draft of the manuscript was written by AK

472 and iteratively reviewed by ECW. All authors commented on previous versions of the
473 manuscript. All authors read and approved the final manuscript.
474 We would like to thank the Cancer Registry of Baden-Württemberg for support of data
475 collection as well as Sein Schmidt and Verena Benz of the Charité-BIH Clinical Study
476 Center. We also thank our project partners Kai Cornelius, Markus Spitz (University of
477 Heidelberg, Germany) and Adrian Thorogood (University of Luxemburg) for conceptual
478 counselling. We are also thankful to Kai Cornelius for establishing contact with the
479 Charité-BIH Clinical Study Center We acknowledge Hellen Kachler and Niamh Sulzbach
480 (both: National Center for Tumor Diseases, Heidelberg University Hospital, Germany) for
481 their assistance in researching the literature, data entry, and linguistic correction of the
482 manuscript.

483

484 **Conflicts of Interest**

485 The authors declare that the research was conducted in the absence of any commercial or
486 financial relationships that could be construed as a potential conflict of interest.

487

488 **References**

- 489 1. Jungkunz M, Köngeter A, Mehlis K, Winkler EC, Schickhardt C. Secondary Use of Clinical Data
490 in Data-Gathering, Non-Interventional Research or Learning Activities: Definition, Types, and a
491 Framework for Risk Assessment. *J Med Internet Res*. 2021;23(6):e26631.
- 492 2. Semler SC, Wissing F, Heyder R. German Medical Informatics Initiative. *Methods Inf Med*.
493 2018;57(S 01):e50-e6.
- 494 3. Hutchings E, Loomes M, Butow P, Boyle FM. A systematic literature review of researchers' and
495 healthcare professionals' attitudes towards the secondary use and sharing of health administrative
496 and clinical trial data. *Systematic Reviews*. 2020;9(1):1-27.

- 497 4. Monaghan T, Manski-Nankervis J-A, Canaway R. Big data or big risk: general practitioner,
498 practice nurse and practice manager attitudes to providing de-identified patient health data from
499 electronic medical records to researchers. *Australian Journal of Primary Health*. 2021;26(6):466-71.
- 500 5. Hodgkins AJ, Mullan J, Mayne DJ, Boyages CS, Bonney A. Australian general practitioners'
501 attitudes to the extraction of research data from electronic health records. *Aust J Gen Pract*.
502 2020;49(3):145-50.
- 503 6. Ipsos MORI. The One-Way Mirror: Public attitudes to commercial access to health data - Report
504 prepared for the Wellcome Trust. 2016.
- 505 7. Vezyridis P, Timmons S. Resisting big data exploitations in public healthcare: free riding or
506 distributive justice? *Sociology of health & illness*. 2019;41(8):1585-99.
- 507 8. Mayo RM, Summey JF, Williams JE, Spence RA, Kim S, Jagsi R. Qualitative Study of Oncologists'
508 Views on the CancerLinQ Rapid Learning System. *Journal of oncology practice*. 2017;13(3):176-84.
- 509 9. Köngeter A, Jungkunz M, Winkler EC, Schickhardt C, Mehlis K. Sekundärnutzung klinischer
510 Daten aus der Patientenversorgung für Forschungszwecke: Eine qualitative Interviewstudie zu Nutzen-
511 und Risikopotenzialen aus Sicht von Expertinnen und Experten für den deutschen Forschungskontext.
512 In: Richter G, Loh W, Buyx A, Graf von Kielmansegg S, editors. *Datenreiche Medizin und das Problem*
513 *der Einwilligung*. Berlin, Heidelberg: Springer; 2022. p. 185-210.
- 514 10. Cumyn A, Dault R, Barton A, Cloutier A-M, Ethier J-F. Citizens, research ethics committee
515 members and researchers' attitude toward information and consent for the secondary use of health
516 data: Implications for research within learning health systems. *J Empir Res Hum Res Ethics*.
517 2021;16(3):165-78.
- 518 11. Perera G, Holbrook A, Thabane L, Foster G, Willison DJ. Views on health information sharing
519 and privacy from primary care practices using electronic medical records. *Int J Med Inform*.
520 2011;80(2):94-101.
- 521 12. Köngeter A, Schickhardt C, Jungkunz M, Susanne B, Mehlis K, Winkler EC. Patients' willingness
522 to provide their clinical data for research purposes and acceptance of different consent models:

- 523 Findings from a representative survey of cancer patients in Germany. *J Med Internet Res* (forthcoming).
524 2022.
- 525 13. Spector-Bagdady K, Krenz CD, Brummel C, Brenner JC, Bradford CR, Shuman AG. “My Research
526 Is Their Business, but I'm Not Their Business”: Patient and Clinician Perspectives on Commercialization
527 of Precision Oncology Data. *The oncologist*. 2020;25(7):620-6.
- 528 14. Arndt BG, Beasley JW, Watkinson MD, Temte JL, Tuan WJ, Sinsky CA, et al. Tethered to the
529 EHR: Primary Care Physician Workload Assessment Using EHR Event Log Data and Time-Motion
530 Observations. *Ann Fam Med*. 2017;15(5):419-26.
- 531 15. de Hoop T, Neumuth T. Evaluating Electronic Health Record Limitations and Time Expenditure
532 in a German Medical Center. *Appl Clin Inform*. 2021;12(05):1082-90.
- 533 16. Adler-Milstein J, Zhao W, Willard-Grace R, Knox M, Grumbach K. Electronic health records and
534 burnout: Time spent on the electronic health record after hours and message volume associated with
535 exhaustion but not with cynicism among primary care clinicians. *J Am Med Inform Assoc*.
536 2020;27(4):531-8.
- 537 17. Bruland P, Doods J, Brix T, Dugas M, Storck M. Connecting healthcare and clinical research:
538 Workflow optimizations through seamless integration of EHR, pseudonymization services and EDC
539 systems. *Int J Med Inform*. 2018;119:103-8.
- 540 18. Raymond L, Paré G, Ortiz de Guinea A, Poba-Nzaou P, Trudel M-C, Marsan J, et al. Improving
541 performance in medical practices through the extended use of electronic medical record systems: a
542 survey of Canadian family physicians. *BMC Med Inform Decis Mak*. 2015;15(1):27.
- 543 19. Ballantyne A. How should we think about clinical data ownership? *Journal of Medical Ethics*.
544 2020;46(5):289-94.
- 545 20. Salomon RM, Blackford JU, Rosenbloom ST, Seidel S, Clayton EW, Dilts DM, et al. Openness of
546 patients' reporting with use of electronic records: psychiatric clinicians' views. *J Am Med Inform Assoc*.
547 2010;17(1):54-60.

- 548 21. Krahe MA, Wolski M, Mickan S, Toohey J, Scuffham P, Reilly S. Developing a strategy to improve
549 data sharing in health research: A mixed-methods study to identify barriers and facilitators. *Health Inf*
550 *Manag [Internet]*. 2020:1833358320917207.
- 551 22. Orton ML, Nilsen P, Nelson Follin N, Dannapfel P. Is It Possible for Registered Nurses and
552 Physicians to Combine Research and Clinical Work to Facilitate Evidence-Based Practice? *Worldviews*
553 *Evid Based Nurs*. 2021;18(1):15-22.
- 554 23. Varhol RJ, Randall S, Boyd JH, Robinson S. Australian General Practitioner Perceptions to
555 Sharing Clinical Data for Secondary Use: A Mixed Method Approach. *Research Square [Preprint]*. 2021.
- 556 24. Shabani M, Thorogood A, Borry P. Who should have access to genomic data and how should
557 they be held accountable? Perspectives of Data Access Committee members and experts. *Eur J Hum*
558 *Genet*. 2016;24:1671-5.
- 559 25. Grava-Gubins I, Scott S. Effects of various methodologic strategies: survey response rates
560 among Canadian physicians and physicians-in-training. *Can Fam Physician*. 2008;54(10):1424-30.
- 561




Figure 1